Houston Methodist scientists have developed a nanodevice to deliver immunotherapy without side effects to treat triple-negative breast cancer. Inserted straight into a tumor, this nanofluidic seed makes it possible to deliver a one-time, sustained-release dose that would eliminate the need for patients to undergo several IV treatments over time.
All news from Hematology & Oncology
Researchers from The Ottawa Hospital and the University of Ottawa have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia (AML) and a diagnostic test to determine which AML patients would most likely benefit from this treatment.
A new blood test for children with brain tumors offers a safer approach than surgical biopsies and may allow doctors to measure the effectiveness of treatment even before changes are identified on scans, according to research led by UCSF Benioff Children's Hospitals and Children's National Health System.
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could improve AML survival rates, which have not budged in recent years.
A new study by researchers at Intermountain Healthcare in Salt Lake City has found that patients with low-risk blood clots may be better off receiving treatment at home versus being admitted to the hospital.
Recently published results of phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy, which is the standard of care.
The US Food and Drug Administration (FDA) has approved antihemophilic factor [recombinant] PEGylated-aucl (Jivi, Bayer) for the routine prophylactic treatment of hemophilia A in previously treated adults and in children and adolescents aged 12 years or older.
The first study to look at out-of-pocket expenses faced by breast cancer survivors in the United States shows that women with adverse treatment effects, such as chronic lymphedema, carry a particularly large economic burden that has a profound and lasting impact on their financial future.
UNSW researchers have discovered a new way to detect ultralow levels of microRNA in a blood sample which could make the diagnosis of cancer and other illnesses quicker and more efficient.